We are pleased to announce that the phase I single-dose clinical trial for the new molecular entity RTU-1096 has been completed. RTU-1096 is a vascular adhesion protein-1 (VAP-1) inhibitor having anti ...
Biotie to continue development of and maintain global rights to BTT-1023, its novel VAP-1 antibody for inflammatory disease Biotie announced today that it maintains global development and ...
SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (“Kubota Vision”), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), ...
FOSTER CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small ...
R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with a group led by Professor Susumu Ishida and Associate Professor Kousuke Noda of the Department of Ophthalmology, Graduate ...
Please provide your email address to receive an email when new articles are posted on . Terns Pharmaceuticals Inc. announced initiation of a phase 1b clinical trial assessing TERN-201 for the ...
Roche (SIX: RO, ROG: OTCQX: RHHBY) and Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary Proximagen Ltd., today announced a worldwide agreement for the further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results